(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 60.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.93%.
Vir Biotechnology's revenue in 2026 is $16,860,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $1,171,571,894, with the lowest VIR revenue forecast at $166,393,538, and the highest VIR revenue forecast at $2,237,408,765. On average, 10 Wall Street analysts forecast VIR's revenue for 2027 to be $2,713,077,249, with the lowest VIR revenue forecast at $409,027,594, and the highest VIR revenue forecast at $7,482,283,346.
In 2028, VIR is forecast to generate $11,359,837,113 in revenue, with the lowest revenue forecast at -$204,513,797 and the highest revenue forecast at $51,975,720,705.